ATCC and BioAgilytix have entered a partnership to develop assay systems, which can be used for testing drug potency, stability testing and other applications.
According to the agreement, the two partners will jointly develop, validate and execute the cell-based assays, to evaluate the potency and stability of therapeutic products and develop their safety and efficacy profiles.
The partnership enables ATCC and BioAilytix to accelerate and enhance biopharmaceutical research and development (R&D).
Sirenas and California Institute for Biomedical Research (Calibr) have announced that they will enter a co-development agreement to develop significant biological capabilities of small molecules in oncology, neuroscience, regenerative medicine and neglected diseases.
The agreement will provide Calibr access to Sirenas’ marine-derived chemistry diversity, Atlantis data mining technology and synthetic chemistry expertise, which will help examine the compounds using biological assays and pre-clinical disease models.
The agreement enables the partners to discover and develop novel compounds through defined pre-clinical and clinical studies.
Nektar Therapeutics plans to raise $175.5 million through the underwritten public offering of 13 million shares of its common stock.
J.P. Morgan Securities is acting as sole book-running manager and Sidley Austin is acting as legal advisor for the offering.
The company plans to invest the funds for general corporate purposes, to increase the working capital and develop its drug candidates, as well as for pre-clinical programmes.
Puma Biotechnology has announced plans to raise gross proceeds of $150 million through underwritten public offering of its common stock shares.
Citigroup Global markets and J.P. Morgan Securities are acting as book-running managers, while Latham & Watkins is acting as legal advisor for the offering.
The company plans to use the funds for the further development of its drug candidates, R&D, clinical trial programmes and also for general corporate purposes and to increase the working capital.
True North Therapeutics has raised $45 million in a series D venture financing round led by HBM Healthcare Investments, Redmile Group and Perceptive Advisors. The financing round was co-led by Franklin Templeton Investments.
The company plans to invest the proceeds for advancement of the development of TNT009 for cold agglutinin disease (CAD) and other rare diseases.